FY2029 Earnings Forecast for Kura Oncology Issued By Wedbush

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Wedbush issued their FY2029 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Thursday, February 6th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of $2.60 for the year. Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other research analysts have also weighed in on the stock. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Jefferies Financial Group dropped their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. UBS Group started coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Price Performance

NASDAQ KURA opened at $8.79 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market capitalization of $683.55 million, a price-to-earnings ratio of -3.72 and a beta of 0.78. The company has a 50 day simple moving average of $8.69 and a 200-day simple moving average of $14.87. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KURA. nVerses Capital LLC bought a new position in Kura Oncology during the third quarter worth $25,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the fourth quarter worth about $90,000. Corient Private Wealth LLC bought a new position in Kura Oncology during the fourth quarter valued at about $109,000. China Universal Asset Management Co. Ltd. raised its holdings in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after acquiring an additional 1,750 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology during the 3rd quarter worth approximately $146,000.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,255 shares of company stock worth $100,739. 5.50% of the stock is currently owned by insiders.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.